« Previous
Next »
Titles
- State Pharmacy Assistance Programs vs. Medicare prescription drug plans: how do they contain rising costs?1
- State biosimilar substitution laws could reduce consumer access and savings1
- Strategic analysis & intelligence (SAI) report: the tier 4 phenomenon : shifting the high cost of drugs to consumers1
- The ABCs of APCDs: how states are using claims data to understand and improve care1
- The Commonwealth Fund health care opinion leaders survey: Medicare Part D1
- The Medi-Cal prescription drug benefit: an overview1
- The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection: a technology assessment : final report1
- The effect of Medicare Part D on evergreening, generic entry, and drug prices1
- The rising cost of specialty drugs drove spending increases for people with multiple sclerosis1
- Top spenders among commercially-insured: increased spending concentration and consistent turnover from 2013 to 20151
- Trends in P2Y12 receptor inhibitor use and adherence after percutaneous coronary intervention, 2008-20161
- What can the United States learn from pharmaceutical spending controls in France?1
- What's the latest on Medicare drug price negotiations?1
- What’s the latest on Medicare drug price negotiations?1